The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock and this lucrative market.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The US Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over.

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

If you have sleep apnea and obesity, tirzepatide Zepbound may offer relief and support weight loss. Ask your doctor if it’s a ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...